Comparing Two Malaria Treatments in Zambian Children
Author Information
Author(s): Nambozi Michael, Van Geertruyden Jean-Pierre, Hachizovu Sebastian, Chaponda Mike, Mukwamataba Doreen, Mulenga Modest, Ubben David, D'Alessandro Umberto
Primary Institution: Tropical Disease Research Center, Zambia
Hypothesis
Does dihydroartemisinin-piperaquine (DHA/PQP) have similar efficacy, safety, and tolerability as artemether-lumefantrine (AL) for treating uncomplicated malaria in children?
Conclusion
DHA/PQP was as effective and safe as AL for treating uncomplicated malaria in children, with fewer new infections observed in the DHA/PQP group.
Supporting Evidence
- No early treatment failures were observed.
- At day 28, the uncorrected ACPR was 92% for DHA/PQP and 74% for AL.
- Fewer recurrent infections were seen in the DHA/PQP group compared to AL.
Takeaway
This study looked at two medicines for malaria in kids. One medicine worked just as well as the other, but it caused fewer new infections.
Methodology
304 children aged 6-59 months were randomized to receive either DHA/PQP or AL and followed for 42 days.
Potential Biases
Potential bias due to the open-label design.
Limitations
The study was not blinded, which may influence the evaluation of tolerability.
Participant Demographics
Children aged 6-59 months with uncomplicated malaria.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95%CI: 1.89-8.74
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website